<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770090</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0090</org_study_id>
    <nct_id>NCT04770090</nct_id>
  </id_info>
  <brief_title>Research of Circulating Tumor Cells Released During Cervical Cancer Surgery</brief_title>
  <acronym>C-CTC</acronym>
  <official_title>Preliminary Descriptive Exploratory Pilot Study Research of Circulating Tumor Cells Released During Cervical Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de NÄ«mes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire de cellules circulantes rares humaines</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical cancer is a rare pathology. Recent studies showed that the risk of recurrence is&#xD;
      higher for patients treated by coelioscopy in comparison with laparotomy. It could be&#xD;
      explained by the spread of circulating tumor cells (CTC) due to tumor mobilization during&#xD;
      coelioscopy.&#xD;
&#xD;
      The primary goal is to evaluate the spread of CTC during surgery on peripheral blood samples.&#xD;
&#xD;
      The secondary outcome is to evaluation the disease-free survival at 3 and 5 years&#xD;
      postoperatively.&#xD;
&#xD;
      20 patients with early stage cervical (IA1 to IB2) eligible to coelioscopic surgery will be&#xD;
      included.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CTC detection could be a pronostic factor for cancer evolution. Cervical cancer is a rare&#xD;
      pathology with increased death rate.&#xD;
&#xD;
      Despite recommendations for coelioscopic treatment of &lt; 4cm cervical cancers, recent studies&#xD;
      showed that the risk of recurrence is higher for patients treated by coelioscopy in&#xD;
      comparison with laparotomy. It could be explained by the spread of circulating tumor cells&#xD;
      (CTC) due to tumor mobilization during coelioscopy.&#xD;
&#xD;
      Hypothesis : Mobilization of the tumor during coelioscopy leads to CTC spread. This spread&#xD;
      could explain the recurrence of cervical cancer.&#xD;
&#xD;
      This pilot study will evaluate the possibility of CTC detection during surgery. The primary&#xD;
      goal is to evaluate the spread of CTC during surgery on peripheral blood samples.&#xD;
&#xD;
      The secondary outcome is to evaluation the disease-free survival at 3 and 5 years&#xD;
      postoperatively.&#xD;
&#xD;
      20 patients with early stage cervical (IA1 to IB2) eligible to coelioscopic surgery will be&#xD;
      included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2021</start_date>
  <completion_date type="Anticipated">April 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of circulating tumor cell detected after cervical cancer surgery.</measure>
    <time_frame>Within 48 hours after surgery.</time_frame>
    <description>Detection of the presence of at least one circulating tumor cell from blood samples taken during surgery (one CTC per 7.5mL of blood or increase of at least one CTC if CTC is present pre-operatively)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of disease-free survival</measure>
    <time_frame>Two points at the 3rd and 5th years</time_frame>
    <description>The disease-free survival will be evaluated at 3 and 5 years post-operatively</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cervical Cancer Stage IA1</condition>
  <condition>Cervical Cancer Stage IB1</condition>
  <condition>Cervical Cancer Stage IA2</condition>
  <condition>Cervical Cancer Stage IB2</condition>
  <arm_group>
    <arm_group_label>Early stage cervical cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with cervical cancer eligible for surgery, stage IA1 to IB2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Peripheral blood samples at the beginning of surgery, after pneumoperitoneum creation and uterine pedicles coagulation.</description>
    <arm_group_label>Early stage cervical cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  &gt;18 years old&#xD;
&#xD;
          -  Cervical cancer confirmed by histology&#xD;
&#xD;
          -  Early stage : IA1 to IB2&#xD;
&#xD;
          -  Histology : epidermoid carcinoma and adenocarcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  advanced stage&#xD;
&#xD;
          -  concomitant cancer&#xD;
&#xD;
          -  participation to other study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gauthier Rathat, M.D</last_name>
    <phone>+33.4.67.33.64.21</phone>
    <email>g-rathat@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martha Duraes, M.D</last_name>
    <phone>+33.6.31.32.91.58</phone>
    <email>duraesmartha@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of gynaecology, Montpellier University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Martha DURAES, M.D</last_name>
      <phone>+33.6.31.32.91.58</phone>
      <email>duraesmartha@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>March 5, 2021</last_update_submitted>
  <last_update_submitted_qc>March 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical cancer</keyword>
  <keyword>Circulating tumor cell</keyword>
  <keyword>Coelioscopy</keyword>
  <keyword>Disease-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

